Bora Pharmaceuticals is a premier international CDMO headquartered in Taiwan. Bora provides early-phase clinical through commercial manufacturing with full packaging capabilities. Their services range from cell line development and formulation to analytical services and clinical cGMP manufacturing. The company also provides tailored development and end-to-end manufacturing services to biologics developers. Bora owns and operates three state-of-the-art cGMP manufacturing facilities across Asia and North America, servicing more than 100 markets around the world. In 2024, they expanded their U.S. operations by acquiring Upsher-Smith Laboratories, a generics manufacturer and marketer based in Minnesota.